- Recent IPO Insys Therapeutics (INSY +23%) posts its first earnings report since its debut, easily topping Q2 estimates as revenue nearly doubled from the previous quarter.
- Subsys generated $18.5M in net revenue, up 90.8% Q/Q from $9.7M in Q1.
- Gross margin was 86%, compared to 34% for Q212, primarily a result of a big jump in sales of Subsys which has a higher gross margin than Dronabinol.
Recent IPO Insys Therapeutics soars after posting a solid Q2
Aug 13 2013, 11:00 ET